Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) EBIT Margin (2020 - 2022)

Elicio Therapeutics filings provide 3 years of EBIT Margin readings, the most recent being 954.36% for Q2 2022.

  • On a quarterly basis, EBIT Margin rose 242415.0% to 954.36% in Q2 2022 year-over-year; TTM through Mar 2023 was 3946.09%, a 382848.0% decrease, with the full-year FY2022 number at 1031.42%, down 88852.0% from a year prior.
  • EBIT Margin hit 954.36% in Q2 2022 for Elicio Therapeutics, down from 878.94% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 621.63% in Q4 2020 to a low of 5374.39% in Q1 2021.
  • Median EBIT Margin over the past 3 years was 1079.32% (2021), compared with a mean of 1639.49%.
  • Biggest five-year swings in EBIT Margin: plummeted -100966bps in 2021 and later soared 449545bps in 2022.
  • Elicio Therapeutics' EBIT Margin stood at 621.63% in 2020, then crashed by -91bps to 58.22% in 2021, then tumbled by -1739bps to 954.36% in 2022.
  • The last three reported values for EBIT Margin were 954.36% (Q2 2022), 878.94% (Q1 2022), and 58.22% (Q4 2021) per Business Quant data.